Wolf, GB
Alexander Wolf, Oxford GB
Patent application number | Description | Published |
---|---|---|
20140045930 | ASSAY FOR ARGINYL HYDROXYLASE ACTIVITY - The present invention relates to assays for monitoring activity of YcfD activity, in particular, to assays for identifying modulators of YcfD activity. The present invention also relates to the use of YcfD inhibitors as antibiotics. The invention also relates to methods for introducing hydroxyarginine residues into proteins. | 02-13-2014 |
20140051106 | METHOD FOR ASSAYING OGFOD1 ACTIVITY - The present invention relates to assays for monitoring activity of OGFOD1 activity, in particular, to assays for identifying modulators of OGFOD1 activity. The invention also relates to assays to monitor the prolyl hydroxylase activity of OGFOD1 on its substrate, the human ribosomal protein RPS23. The invention also enables the introduction of 3-hydroxyprolyl residues into peptides and proteins. | 02-20-2014 |
Bettina Wolf, East Leake GB
Patent application number | Description | Published |
---|---|---|
20100112139 | Foaming Agents Comprising Hydrophobin - Gelled particles having a largest dimension of more than 0.1 μm which are coated with hydrophobin are provided. Aerated and aeratable compositions comprising the particles are also provided. | 05-06-2010 |
20140302220 | EMULSION STABILISATION - The present invention relates to the use of cocoa particles as the emulsifier system for the stabilization of a water-in-oil or oil-in-water emulsion. In another aspect there is now provided a confectionery product comprising cocoa particles as the emulsifying agent that does not contain any synthetic or artificial emulsifiers, and to methods for producing such confectionery product. | 10-09-2014 |
Charles R. Wolf, Perth GB
Patent application number | Description | Published |
---|---|---|
20120029079 | PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS - The molecules of formula (I) are useful in treating diabetes, obesity, hypercholesterolaemia, hyperlipidaemia, cancer, inflammation or other conditions in which modulation of lipis of eicosanoid status or functions may be desirable. Formula (I): Z | 02-02-2012 |
Charles Roland Wolf, Dundee GB
Patent application number | Description | Published |
---|---|---|
20090013417 | Transgenic Animals for Assessing Drug Metabolism and Toxicity in Man - A method of introducing at least one human cytochrome P450 into a non-human animal c ell in which corresponding endogenous P450 enzyme activities have been disabled, thus the method provides a way of using a non-human animal cell to make predictions regarding P450-mediated metabolism in a human. The present invention also provides transgenic non-human animals produced by the method of the invention and uses therefor, especially in assessing xenobiotic/drug metabolism and toxicity. | 01-08-2009 |
20100138935 | Detection of cellular stress - We provide reporter gene constructs incorporating nucleic acid sequences from a promoter region of a gene or set of genes whose expression is modified in response to external or internal changes in the cellular environment such as biochemical stress or toxic conditions. The promoters are operatively linked to nucleic acid sequences chosen on the basis of the ease with which their transcription and/or translation products may be assayed so that the reporter gene constructs can provide a system capable of detecting intracellular conditions. Also described are transfected cell lines including the constructs and transgenic non-human animal models including the constructs. | 06-03-2010 |
20100333222 | KNOCKOUT MICE FOR A P450 GENE CLUSTER - The invention relates to the generation of mouse models of drug metabolism in which clusters of genes that are involved in drug metabolism have been knocked out. The development of new drugs and chemicals for therapeutic use or for other purposes is extremely complex. Of particular importance is the understanding of how these chemical agents are handled in the body, whether they have appropriate pharmacokinetics and whether, as a consequence of metabolism, any safety issues arise. Many of the proteins that are involved in the metabolism, disposition and elimination of drugs are members of multigene families that exhibit very marked species differences in gene number, function and regulation. For these reasons, experiments carried out in laboratory animals to establish routes of metabolism or toxicity can be severely compromised and, as a consequence, do not faithfully represent the human situation. One example of this complexity is reflected in the mammalian cytochrome P450 system, where the sizes of multigene families of proteins which carry out particular metabolic functions vary enormously between species. | 12-30-2010 |
20110119780 | SCREENING FOR NON-GENOTOXIC CARCINOGENS - The invention relates to a method for screening for the effects of non-genotoxic carcinogens in an animal model. The invention also relates to animal models that are suitable for use in such a method, and cell lines derived from these animals for in vitro screening purposes. More specifically, the invention relates to a transgenic rodent animal which has been humanised for the nuclear transcription factors CAR, PXR and PPARα, and in which the endogenous equivalent genes have been rendered inoperable. | 05-19-2011 |
20130029928 | COMPOSITIONS COMPRISING PERFLUOROOCTANOIC ACID - There is provided compositions comprising perfluorooctanoic acid (PFOA) or a salt, derivative or variant thereof. There is also provided uses, methods therapeutic systems and combination therapies relating to PFOA. | 01-31-2013 |
Charles Roland Wolf, Dundee Technopole GB
Patent application number | Description | Published |
---|---|---|
20100093017 | Metabolically Competent Cell Lines - The present invention provides cell lines that have been transfected with adenovirus expression vectors so that they express at least one metabolically competent or functional cytochrome P450 enzyme. The invention also includes methods of their use, especially in toxicology screens. | 04-15-2010 |
Charles Roland Wolf, Inchture GB
Patent application number | Description | Published |
---|---|---|
20090010888 | Use of cytochrome P450 reductase as insecticidal target - The invention provides a method of enhancing the effectiveness of pesticides, as well as pesticidal formulations. Furthermore, it also provides the means for the de novo rational design of pesticides. The present invention also relates to a method of screening agents for potential use in insecticides, particularly against mosquitoes. | 01-08-2009 |
20100240751 | Methods - A perfluoroctanoic acid or a salt or an ester thereof; perfluorosuberic acid, perfluoroheptanoic acid, perfluorohexanoic acid, perfluoropentanoic acid, perfluorobutanoic acid or perfluoropropionic acid or a salt or an ester any thereof; or perfluoroctane are useful in treating diabetes, obesity, hypercholesterolaemia, hyperlipidaemia, cancer, inflammation or other conditions in which modulation of lipid or eicosanoid status or function may be desirable. | 09-23-2010 |
Charles Roland Wolf, Perthshire GB
Patent application number | Description | Published |
---|---|---|
20100235928 | TRANSGENIC ANIMALS FOR ASSESSING DRUG METABOLISM AND TOXICITY - The present invention relates to transgenic non-human animals, tissues or cells derived therefrom and methods of producing them. The transgenic non-human animals or tissues or cells derived therefrom provide a system capable of expressing human proteins responsible for drug metabolism in place of the homologous endogenous non-human animal proteins and for the controlled expression of human genes introduced into the animal so that the expression of the human genes is regulated in a manner more closely analogous to that seen in vivo in humans. | 09-16-2010 |
Roland Wolf, Dundee GB
Patent application number | Description | Published |
---|---|---|
20100028460 | IMPROVEMENTS IN RELATION TO CANCER THERAPY - The present invention relates to an improved assay for identifying compounds that may be of use in conjunction with cancer chemotherapeutic agents and anti-proliferative agents, to improve efficacy of such agents and/or render effective compounds with relatively little therapeutic activity. There is also provided a class of compounds of formula (I) and retinoids identified by said assay which may be used in a combination therapy, with current and novel agents, to treat cancers and other diseases associated with abnormal host cell proliferation, such as psoriasis. | 02-04-2010 |
20120309087 | CANCER THERAPY - The present invention relates to an improved assay for identifying compounds that may be of use in conjunction with cancer chemotherapeutic agents and anti-proliferative agents, to improve efficacy of such agents and/or render effective compounds with relatively little therapeutic activity. There is also provided a class of compounds identified by said assay which may be used in a combination therapy, with current and novel agents, to treat cancers and other diseases associated with abnormal host cell proliferation, such as psoriasis. | 12-06-2012 |